15 recruiting, 4 active not recruiting, 3 terminated, 2 completed. 15 Phase 2, 6 Phase 1, 6 Phase 3, 1 Early Phase 1.
Follow Opdualag: new trials by email Literature Review of Opdualag trials Research Report on Opdualag
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG Opdualag - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Not yet recruiting | Nationwide Children's Hospital | 12 | 2027-03-01 | 2026-09-09 |
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma Opdualag, Nivolumab - Cutaneous Melanoma, Melanoma Stage IV | Phase 2 | Recruiting | University Health Network, Toronto | 54 | 2026-11-30 | 2026-10-13 |
| Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases | Phase 1 / Phase 2 | Recruiting | University of Wisconsin, Madison | 15 | 2026-10-01 | 2026-09-29 |
| Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma Fianlimab + Cemiplimab, Relatlimab + Nivolumab - Locally Advanced Melanoma | Recruiting | John Kirkwood | 20 | 2025-11-19 | 2025-11-26 | |
| Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma Nivolumab, Relatlimab plus Nivolumab - Basal Cell Carcinoma | Phase 2 | Recruiting | University of California, San Diego | 30 | 2025-08-21 | 2026-07-28 |
| Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases Ipilimumab, Nivolumab + Relatlimab FDC - Melanoma, Brain Metastases | Phase 2 | Recruiting | Stanford University | 60 | 2025-08-06 | 2026-05-18 |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma IMA203, nivolumab plus relatlimab, lifileucel - Melanoma, Cutaneous Malignant | Phase 3 | Recruiting | Immatics US, Inc. | 360 | 2025-01-14 | 2026-08-18 |
| Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors Cytokine-induced memory-like natural killer cells, Relatilmab, Nivolumab - Advanced Melanoma, Metastatic Melanoma | Phase 1 | Suspended | Washington University School of Medicine | 33 | 2024-11-06 | 2026-09-22 |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) fianlimab, cemiplimab, relatlimab+nivolumab - Melanoma | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 560 | 2024-09-09 | 2026-10-07 |
| VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab - Advanced Melanoma | Phase 3 | Recruiting | Replimune, Inc. | 400 | 2024-07-11 | 2026-07-15 |
| Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Paxalisib, Opdualag, Irinotecan (drug) - Childhood Cancer, Childhood Solid Tumor | Phase 1 / Phase 2 | Recruiting | Australian & New Zealand Children's Haematology/Oncology Group | 90 | 2024-07-10 | 2026-01-28 |
| Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination - Cutaneous Squamous Cell Carcinoma | Phase 2 | Recruiting | Melanoma Institute Australia | 20 | 2024-06-21 | 2026-07-08 |
| IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) Brenetafusp, Nivolumab, Nivolumab + Relatlimab - Advanced Melanoma | Phase 3 | Recruiting | Immunocore Ltd | 680 | 2024-06-05 | 2026-02-25 |
| Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma Nivolumab, Nivolumab + Relatlimab, Ipilimumab - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 90 | 2024-05-17 | 2026-04-01 |
| Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination - Merkel Cell Carcinoma | Phase 2 | Recruiting | Melanoma Institute Australia | 20 | 2024-03-11 | 2026-02-17 |
| A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab - Melanoma | Phase 2 | Active not recruiting | Bristol-Myers Squibb | 100 | 2023-11-06 | 2026-09-14 |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors KB707, Opdualag, KEYTRUDA ®( Pembrolizumab) - Cancer, Melanoma Stage III | Phase 1 / Phase 2 | Recruiting | Krystal Biotech, Inc. | 240 | 2023-10-31 | 2025-05-18 |
| A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma Relatlimab and nivolumab fixed dose combination (FDC) - Stage II Melanoma | Phase 2 | Active not recruiting | Melanoma Institute Australia | 20 | 2023-08-14 | 2026-02-05 |
| A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma IO102/IO103, Nivolumab-Relatlimab - Melanoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 43 | 2023-06-09 | 2026-06-01 |
| Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases Nivolumab, Ipilimumab, Nivolumab + Relatlimab - Metastatic Melanoma, Metastasis to Brain | Early Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 1 | 2023-06-06 | 2026-04-06 |
Showing 20 of 26. Sign in to see all of them.
Melanoma (15) · Brain Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Recurrence (2) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Central Nervous System Neoplasms (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Diffuse Intrinsic Pontine Glioma (1) · Glioma (1) · Lymphoma (1) · Melanoma, Cutaneous Malignant (1)
Bristol-Myers Squibb (3) · Melanoma Institute Australia (3) · H. Lee Moffitt Cancer Center and Research Institute (2) · Australian & New Zealand Children's Haematology/Oncology Group (1) · Carlo Contreras (1) · Dan Zandberg (1) · Immatics US, Inc. (1) · Immunocore Ltd (1) · Iovance Biotherapeutics, Inc. (1) · John Kirkwood (1) · Krystal Biotech, Inc. (1) · Memorial Sloan Kettering Cancer Center (1) · Nationwide Children's Hospital (1) · Regeneron Pharmaceuticals (1) · Replimune, Inc. (1)
United States (20) · Canada (8) · Australia (7) · Germany (6) · Spain (6) · United Kingdom (6) · France (5) · Greece (4) · Italy (4) · Switzerland (4) · Austria (3) · Belgium (3) · Brazil (3) · Chile (3) · Czechia (3)
Ahmad Tarhini, MD, PhD (1) · Alice Y Zhou, M.D., Ph.D. (1) · Allison Betof, MD, PhD (1) · Carlo M Contreras, MD (1) · Cedrik Britten, M.D. (1) · Dan P Zandberg, MD (1) · Daniel Morgenstern, Dr (1) · David Chien, MD (1) · David Ziegler, Prof (1) · Georgina Long (1) · Georgina V Long (1) · Ines Da Silva (1)
PMID 35880942, PMID 41109920, PMID 42770835
2023 (2), 2018 (1)